Utility of Deceased Expanded-Criteria Donors in Kidney Transplantation: A Single-Center Experience †
Abstract
:1. Introduction
2. Methods
2.1. Patients
2.2. Biostatistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Collins, A.J.; Foley, R.N.; Gilbertson, D.T.; Chen, S.C. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int. Suppl. 2015, 5, 2–7. [Google Scholar]
- Noble, J.; Jouve, T.; Malvezzi, P.; Süsal, C.; Rostaing, L. Transplantation of Marginal Organs: Immunological Aspects and Therapeutic Perspectives in Kidney Transplantation. Front. Immunol. 2020, 10, 3142. [Google Scholar]
- Wang, Z.; Durai, P.; Tiong, H.Y. Expanded criteria donors in deceased donor kidney transplantation—An Asian perspective. Indian J. Urol. 2020, 36, 89–94. [Google Scholar] [PubMed]
- Ko, K.J.; Kim, Y.H.; Kwon, K.H.; Kim, M.H.; Jun, K.W.; Hwang, J.K.; Kim, S.D.; Park, S.C.; Kim, J.I.; Yun, S.S.; et al. Kidney Transplantation Using Expanded-Criteria Deceased Donors: A Comparison With Ideal Deceased Donors and Non-Expanded-Criteria Deceased Donors. Transplant. Proc. 2018, 50, 3222–3227. [Google Scholar]
- Salguero, J.; Chamorro, L.; Gomez-Gomez, E.; Robles, J.E.; Campos, J.P. Midterm Outcomes of Kidney Transplantation from Expanded Criteria Donors After Circulatory Death: A Single-Center Retrospective Cohort Study. Exp. Clin. Transplant. 2023, 21, 481–486. [Google Scholar] [CrossRef]
- Oruç, A.; Ersoy, A.; Ayar, Y.; Akgür, S.; Yildiz, A. Exclusion Reasons of Cadaveric Kidney Transplantation Candidates. Turk. J. Nephrol. 2018, 27, 82–86. [Google Scholar]
- Çoban, Ş.; Yıldız, S.; Bozkaya, E.; Derici, Z.S.; Ünlü, M.; Çelik, A.; Sifil, A.; Cavdar, C.; Camsari, T. Evaluation of Morbidity and Patient and Graft Survival in Kidney Transplant Recipients: Experience of Dokuz Eylul University Hospital. Turk. J. Nephrol. 2017, 26, 41–47. [Google Scholar]
- Sexton, D.J.; O’Kelly, P.; Kennedy, C.; Denton, M.; de Freitas, D.G.; Magee, C.; O’Seaghdha, C.M.; Conlon, P.J. Assessing the discrimination of the Kidney Donor Risk Index/Kidney Donor Profile Index scores for allograft failure and estimated glomerular filtration rate in Ireland’s National Kidney Transplant Programme. Clin. Kidney J. 2019, 12, 569–573. [Google Scholar]
- Goussous, N.; De Leon, F.; Alghannam, K.; Howard, B.C.; Than, P.A.; Wang, A.X.; Sageshima, J.; Perez, R.V. Outcomes Using High KDPI Kidneys in Recipients Over 65 y of Age. Transpl. Direct. 2024, 10, e1738. [Google Scholar] [CrossRef]
- Lentine, K.L.; Smith, J.M.; Lyden, G.R.; Miller, J.M.; Dolan, T.G.; Bradbrook, K.; Larkin, L.; Temple, K.; Handarova, D.K.; Weiss, S.; et al. OPTN/SRTR 2022 Annual Data Report: Kidney. Am. J. Transpl. 2024, 24 (Suppl. S1), S19–S118. [Google Scholar] [CrossRef]
- Heemann, U.; Abramowicz, D.; Spasovski, G.; Vanholder, R.; European Renal Best Practice Work Group on Kidney Transplantation. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: A European Renal Best Practice (ERBP) position statement. Nephrol. Dial. Transpl. 2011, 26, 2099–2106. [Google Scholar]
- von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann. Intern Med. 2007, 147, 573–577. [Google Scholar] [PubMed]
- Regıstry of the Nephrology, Dıalysıs and Transplantatıon in Turkey, Regıstry 2019 and 2020. In Mınıstry of Health and Turkısh Socıety of Nephrology Joınt Report; Suleymanlar, G., Ates, K., Seyahi, N., Kocyigit, I., Eds.; Turkish Society of Nephrology Registry Committee: Ankara, Turkey, 2020; pp. 52–53. [Google Scholar]
- Monteoliva, P.B.; Redondo-Pachón, D.; García, E.M.; Calabia, E.R. Kidney transplant outcome of expanded criteria donors after circulatory death. Nefrol. Engl. Ed. 2021, 42, 135–144. [Google Scholar]
- Ma, M.K.; Lim, W.H.; Craig, J.C.; Russ, G.R.; Chapman, J.R.; Wong, G. Mortality among Younger and Older Recipients of Kidney Transplants from Expanded Criteria Donors Compared with Standard Criteria Donors. Clin. J. Am. Soc. Nephrol. 2016, 11, 128–136. [Google Scholar] [PubMed]
- Kuhn, C.; Lang, B.M.; Lörcher, S.; Karolin, A.; Binet, I.; Beldi, G.; Golshayan, D.; Hadaya, K.; Mueller, T.F.; Schaub, S.; et al. Outcome of kidney transplantation from very senior donors in Switzerland—A national cohort study. Transpl. Int. 2021, 34, 689–699. [Google Scholar]
- Molinari, M.; Kaltenmeier, C.; Liu, H.; Ashwat, E.; Jorgensen, D.; Puttarajappa, C.; Wu, C.M.; Mehta, R.; Sood, P.; Shah, N.; et al. Function and longevity of renal grafts from high-KDPI donors. Clin. Transpl. 2022, 36, e14759. [Google Scholar]
- Bae, S.; Massie, A.B.; Thomas, A.G.; Bahn, G.; Luo, X.; Jackson, K.R.; Ottmann, S.E.; Brennan, D.C.; Desai, N.M.; Coresh, J.; et al. Who can tolerate a marginal kidney? Predicting survival after deceased donor kidney transplant by donor-recipient combination. Am. J. Transpl. 2019, 19, 425–433. [Google Scholar]
- Arias-Cabrales, C.E.; Pérez-Sáez, M.J.; Redondo-Pachón, D.; Buxeda, A.; Burballa, C.; Duran, X.; Mir, M.; Crespo, M.; Pascual, J. Relevance of KDPI value and acute rejection on kidney transplant outcomes in recipients with delayed graft function—A retrospective study. Transpl. Int. 2020, 33, 1071–1077. [Google Scholar]
- Jalalzadeh, M.; Mousavinasab, N.; Peyrovi, S.; Ghadiani, M.H. The impact of acute rejection in kidney transplantation on long-term allograft and patient outcome. Nephro-Urol. Mon. 2015, 7, e24439. [Google Scholar]
- Peeters, L.E.J.; Andrews, L.M.; Hesselink, D.A.; de Winter, B.C.M.; van Gelder, T. Personalized immunosuppression in elderly renal transplant recipients. Pharmacol. Res. 2018, 130, 303–307. [Google Scholar]
- Diekmann, F.; Gutiérrez-Dalmau, A.; López, S.; Cofán, F.; Esforzado, N.; Ricart, M.J.; Rossich, E.; Saval, N.; Torregrosa, J.V.; Oppenheimer, F.; et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols. Nephrol. Dial. Transpl. 2007, 22, 2316–2321. [Google Scholar]
- Knight, S.R.; Russell, N.K.; Barcena, L.; Morris, P.J. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: A systematic review. Transplantation 2009, 87, 785–794. [Google Scholar] [PubMed]
- Su, V.C.H.; Greanya, E.D.; Ensom, M.H. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review. Ann. Pharmacother. 2011, 45, 248–257. [Google Scholar] [PubMed]
Donor Type | SCD (n = 92) | ECD (n = 63) | p |
---|---|---|---|
Gender (n, %) | |||
Male | 63 (68.50%) | 38 (60.30%) | 0.381 |
Female | 29 (31.50%) | 25 (39.70%) | |
Age (n) | 41 (20–59) | 62 (42–86) | p < 0.001 |
Donor height (cm) | 170 (150–196) | 170 (150–185) | 0.133 |
Donor kg | 70 (50–115) | 75 (52–115) | 0.065 |
Last urine (cc) | 180 (10–1000) | 100 (20–1400) | 0.023 |
24 h urine (cc) | 4255 (750–14,950) | 3200 (800–7500) | 0.030 |
Donor BMI | 24.71 ± 3.24 | 26.96 ± 3.64 | p < 0.001 |
DM in donor (n, %) | |||
Yes | 0 (0%) | 27 (42.90%) | p < 0.001 |
No | 92 (100%) | 36 (57.10%) | |
HT in donor (n, %) | |||
Yes | 8 (8.70%) | 59 (93.70%) | p < 0.001 |
No | 84 (91.30%) | 4 (6.30%) | |
Cause of death (n, %) | |||
CVA | 62 (67.40%) | 60 (95.20%) | p < 0.001 |
Trauma | 24 (26.10%) | 1 (1.60%) | |
Other | 6 (6.50%) | 2 (3.20%) | |
İntensive care Hospitalization (day) | 3 (1–21) | 3 (1–10) | 0.134 |
Cold ischemia (hour) | 10 (1–21) | 12 (4–36) | 0.020 |
HbsAg (n, %) | |||
Positive | 2 (2.20%) | 3 (4.80%) | 0.397 |
Negative | 90 (97.80%) | 60 (95.20%) | |
antiHbs (n, %) | |||
Positive | 39 (42.40%) | 53 (57.60%) | 0.241 |
Negative | 20 (31.70%) | 43 (68.30%) | |
Yes | 8 (8.70%) | 59 (93.70%) | p < 0.001 |
No | 84 (91.30%) | 4 (6.30%) | |
KDPI (%) | 56 (19–88) | 97 (65–100) | <0.001 |
KDRI (%) | 1.06 (0.73–1.57) | 1.93 (1.16–3.50) | <0.001 |
HLA mismatch (n) | 2 (1–6) | 2 (1–6) | 0.865 |
Recipient Age (n) | SCD (n = 92) 42.50 ± 13.27 | ECD (n = 63) 42.84 ± 14.34 | 0.879 |
---|---|---|---|
HT in recipient (n, %) | |||
Yes | 0 (0%) | 27 (42.90%) | p < 0.001 |
No | 92 (100%) | 36 (57.10%) | |
DM in recipient (n, %) | |||
Yes | 19 (20.70%) | 16 (25.40%) | 0.618 |
No | 73 (79.30%) | 47 (74.60%) | |
Hospitalization after Tx (n, %) | |||
UTI | 20 (21.70%) | 16 (25.40%) | 0.926 |
Pneumonia | 25 (27.20%) | 15 (23.80%) | |
Surgical complication | 11 (12%) | 9 (14.30%) | |
Rejection | 8 (8.70%) | 6 (9.50%) | |
Other | 8 (8.70%) | 3 (4.80%) | |
None | 20 (21.70%) | 14 (22.20%) | |
Graft loss (n, %) | |||
Yes | 12 (13%) | 10 (16.10%) | 0.763 |
No | 80 (87%) | 52 (83.90%) | |
Survey | |||
Alive | 76 (82.60%) | 48 (76.20%) | 0.162 |
Rejection | 5 (5.40%) | 9 (14.30%) | |
Death | 11 (12%) | 6 (9.50%) |
SCD (n = 92) | ECD (n = 63) | p | |
---|---|---|---|
CNI (n, %) | |||
Cyclosporine | 49 (53.30%) | 26 (41.30%) | 0.142 |
Tacrolimus | 43 (46.70%) | 37 (58.70%) | |
MMF (n, %) | |||
Yes | 84 (91.30%) | 55 (87.30%) | 0.592 |
No | 8 (8.70%) | 8 (12.70%) | |
mTOR (n, %) | |||
Yes | 6 (6.50%) | 6 (9.50%) | 0.549 |
No | 86 (93.50) | 57 (90.50%) | |
Primary non-functioning kidney (n, %) | |||
Yes | 0 (0%) | 5 (7.90%) | 0.010 |
No | 92 (100%) | 58 (92.10%) | |
Acute rejection (n, %) | |||
Yes | 19 (20.70%) | 15 (23.80%) | 0.788 |
No | 73 (79.30%) | 48 (76.20%) | |
DGF (n, %) | |||
Yes | 13 (14.10%) | 14 (22.20%) | 0.276 |
No | 79 (85.90%) | 49 (77.80%) | |
ATN (n, %) | |||
Yes | 31 (33.70%) | 20 (31.70%) | 0.936 |
No | 61 (66.30%) | 43 (68.30%) |
SCD (n = 92) | ECD (n = 63) | p | |
---|---|---|---|
Serum creatinine first month (mg/dL) | 1.30 (0.53–8.90) | 1.61 (0.46–14.80) | 0.014 |
Serum creatinine sixth month * | 0.08 (−1:1.28) | −0.03 (−0.84:1.15) | 0.061 |
Serum creatinine twelfth month * | −0.02 (−1:3.24) | 0.01 (−0.85:5.96) | 0.208 |
Serum creatinine final* | −0.04 (−1:9.34) | 0 (−0.82:6.01) | 0.510 |
GFR first month (ml/min/m2) | 57.67 (7–202) | 44 (3.57–202) | 0.005 |
GFR sixth month * | −0.07 (−1:65.26) | 0.04 (−0.59:4.13) | 0.010 |
GFR twelfth month * | −0.05 (−1:7.18) | −0.07 (−0.90:5.66) | 0.572 |
GFR final month * | −0.07 (−1:6.73) | −0 (−0.90:4.77) | 0.445 |
SCD (n = 92) | ECD (n = 63) | |
---|---|---|
Serum urea (mg/dL) | 42 (6–114) | 57 (15–137) |
Serum creatinine (mg/dL) | 1.10 (0.47–6.20) | 1.30 (0.50–4.02) |
Hgb (g/dL) | 11.10 (6.50–17.40) | 12.60 (7.42–15.50) |
Wbc (103/µL) | 14.19 (1.10–29.20) | 14 (1.51–46) |
Na (mmol/L) | 151.50 (12–199) | 153 (68–211) |
K (mmol/L) | 3.69 (1.50–6.40) | 3.60 (2.40–4.90) |
Post-transplant surgical complications | ||
Lymphocele | 31 (33.70%) | 21 (33.30%) |
Hernia | 1 (1.10%) | 3 (4.80%) |
İleus | 2 (2.20%) | 0 (0%) |
Other | 11 (12%) | 8 (12.70%) |
None | 47 (51.10%) | 31 (49.20%) |
Post-transplant medical complications | ||
Drug | 3 (3.30%) | 3 (4.80%) |
Hyperparathyroidism (secondary or tertiary) | 2 (2.20%) | 1 (1.60%) |
TXGMP | 1 (1.10%) | 0 (0%) |
AVN | 9 (9.80%) | 2 (3.20%) |
None | 77 (83.70%) | 57 (90.50%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ayar, Y.; Ersoy, A.; Isiktas Sayilar, E.; Yildiz, A.; Can, F.E.; Oruc, A. Utility of Deceased Expanded-Criteria Donors in Kidney Transplantation: A Single-Center Experience. J. Clin. Med. 2025, 14, 3232. https://doi.org/10.3390/jcm14093232
Ayar Y, Ersoy A, Isiktas Sayilar E, Yildiz A, Can FE, Oruc A. Utility of Deceased Expanded-Criteria Donors in Kidney Transplantation: A Single-Center Experience. Journal of Clinical Medicine. 2025; 14(9):3232. https://doi.org/10.3390/jcm14093232
Chicago/Turabian StyleAyar, Yavuz, Alparslan Ersoy, Emel Isiktas Sayilar, Abdülmecit Yildiz, Fatma Ezgi Can, and Aysegul Oruc. 2025. "Utility of Deceased Expanded-Criteria Donors in Kidney Transplantation: A Single-Center Experience" Journal of Clinical Medicine 14, no. 9: 3232. https://doi.org/10.3390/jcm14093232
APA StyleAyar, Y., Ersoy, A., Isiktas Sayilar, E., Yildiz, A., Can, F. E., & Oruc, A. (2025). Utility of Deceased Expanded-Criteria Donors in Kidney Transplantation: A Single-Center Experience. Journal of Clinical Medicine, 14(9), 3232. https://doi.org/10.3390/jcm14093232